Search
for
Sort by
Research 721–750 of 1000+
- Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in the Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design
- Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata
- Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes
- The Effect of Platelet Rich Plasma on Hair Re‐growth in Patients with Alopecia Areata Totalis: a Clinical Pilot Study
- Simvastatin/Ezetimibe Therapy for Recalcitrant Alopecia Areata: An Open Prospective Study of 14 Patients
- Utility of azathioprine, methotrexate and cyclosporine as steroid‐sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients
- Altered expression of intracellular Toll-like receptors in peripheral blood mononuclear cells from patients with alopecia areata
- Preferential Recognition of Hydroxyl Radical-Modified Superoxide Dismutase by Circulating Autoantibodies in Patients with Alopecia Areata
- Dickkopf-1 Expression in Androgenetic Alopecia and Alopecia Areata in Male Patients
- Evaluation of quality of life scores and family impact scales in pediatric patients with alopecia areata: a cross‐sectional cohort study
- The Hairdex Quality of Life Instrument—A Translation and Psychometric Validation in Patients with Alopecia Areata
- Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- The Role of Ischemia-modified Albumin and Ischemia-modified Albumin to Albumin Ratios in Patients with Alopecia Areata
- Combined Diet and Supplementation Therapy Resolves Alopecia Areata in a Paediatric Patient: A Case Study
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis
- Health‐related quality of life and well‐being in pediatric patients with alopecia areata and their caregivers
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Serum levels of ifn-γ, complement component c3 c4 and vitamin d3 in the prognosis of patients with alopecia areata prospective teachers
- Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Correlation between increased total serum IgE levels and clinical features in alopecia areata patients
- Genetic Polymorphisms of Immunity Regulatory Genes and Alopecia Areata Susceptibility in Jordanian Patients
- Efficacy of therapy with 311nm narrow-band UVB 311nm in the treatment of patients with alopecia areata associated with atopic dermatitis
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IgG and IgA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE